

## Final - October 16, 2018

### MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

1600 Clifton Road, NE, Tom Harkin Global Communications Center, Kent "Oz" Nelson Auditorium

Atlanta, Georgia 30329

October 24-25, 2018

<u>AGENDA ITEM</u>	<u>PURPOSE</u>	<u>PRESIDER/PRESENTER(s)</u>
<b><u>Wednesday, October 24</u></b>		
<b>8:00 Welcome &amp; Introductions</b>		Dr. Amanda Cohn (ACIP Executive Secretary; CDC)
<b>8:30 Hepatitis A Vaccines</b>		
Introduction		Dr. Kelly Moore (ACIP, WG Chair)
Background	Information	Dr. Noele Nelson (CDC/NCHHSTP)
Homelessness as a risk group: Evidence to Recommendation	& Discussion	Dr. Mona Doshani (CDC/NCHHSTP)
Framework and GRADE		
Public comment		
Recommendation vote	<u>Vote</u>	Dr. Noele Nelson (CDC/NCHHSTP)
VFC vote	<u>VFC Vote</u>	Dr. Jeanne Santoli (CDC/NCIRD)
<b>10:15 Break</b>		
<b>10:30 Pneumococcal Vaccines</b>		
Introduction		Dr. Grace Lee (ACIP, WG Chair)
PCV13 Impact on IPD and serotype distribution for the remaining disease burden		Dr. Tamara Pilishvili (CDC/NCIRD)
Incidence of non-Invasive Pneumococcal Pneumonia before and after PCV13 recommendation for adults ≥65yo	Information	Mr. Ryan Gierke (CDC/NCIRD)
U.S. trends in pneumonia hospitalizations	& Discussion	Dr. Fernanda Lessa (CDC/NCIRD)
Economic analysis of PCV13 for adults ≥65 year old		Dr. Charles Stoecker (Tulane University School of Public Health and Tropical Medicine)
Preliminary EtR and GRADE. Summary and timeline		Dr. Almea Matanock (CDC/NCIRD)
<b>12:15 Lunch</b>		
<b>1:30 Adult Immunization Schedule</b>		
Introduction	Information &	Dr. Paul Hunter (ACIP, WG Chair)
Proposed 2019 adult immunization schedule	Discussion	Dr. David Kim (CDC/NCIRD)
<b>2:20 Child/Adolescent Immunization Schedule</b>		
Introduction	Information	Dr. Henry Bernstein (ACIP, WG Chair)
Proposed 2019 child and adolescent immunization schedule	& Discussion	Dr. Candice Robinson (CDC/NCIRD)
Public comment		
Immunization schedules recommendations vote	<u>Vote</u>	Drs. David Kim and Candice Robinson (CDC/NCIRD)
<b>3:00 Break</b>		
<b>3:15 Japanese Encephalitis</b>		
Introduction		Dr. Chip Walter (WG chair)
JE vaccine Evidence to Recommendations	Information &	Dr. Susan Hills (CDC/NCEZID)
JE-VC accelerated schedule recommendation for adults	Discussion	Dr. Susan Hills (CDC/NCEZID)
JE-VC pediatric booster and booster dose recommendations		Dr. Susan Hills (CDC/NCEZID)
Conclusions and next steps		Dr. Susan Hills (CDC/NCEZID)
<b>4:15 Anthrax</b>		
Introduction		Dr. David Stephens (ACIP, WG Chair)
NuThrax®	Information	Dr. Paul- Andre de Lame, Mr. Jeff Shearer (Emergent BioSolutions)
Anthrax antitoxin for PEP		Dr. William Bower (CDC/NCEZID)
<b>5:00 Vaccine Supply</b>		
<b>5:05 Public Comment</b>		
<b>5:20 Adjourn</b>		

## Final - October 16, 2018

### Thursday, October 25

#### **8:00 Agency Updates & Unfinished Business**

CDC, CMS, DoD, DVA, FDA, HRSA, IHS, NIH, NVPO

Information

Dr. Nancy Messonnier (CDC/NCIRD); *Ex Officio* Members

#### **8:30 Human Papillomavirus**

Introduction

Dr. Peter Szilagyi (ACIP, WG Chair)

Vaccine safety update - no association with primary ovarian insufficiency

Ms. Julianne Gee (CDC/NCEZID)

Background - Expanded age indication for 9vHPV GRADE

Information & Discussion

Dr. Lauri Markowitz (CDC/NCIRD)

Dr. Elissa Meites (CDC/NCIRD)

Impact and economic analyses

Dr. Harrell Chesson (CDC/NCHHSTP)

Recommendation options

Dr. Lauri Markowitz (CDC/NCIRD)

#### **10:15 Break**

#### **10:45 General Recommendations**

Introduction

Dr. Paul Hunter (ACIP, WG Chair)

Background and posted changes since April 2017

Information &

Dr. Andrew Kroger (CDC/NCIRD)

Vaccine Administration – Vaccinators with conditions that are contraindications or precautions

Discussion

Dr. Andrew Kroger (CDC/NCIRD)

#### **11:15 Influenza**

Introduction

Dr. Chip Walter

Influenza vaccine effectiveness in preventing influenza-associated hospitalizations during pregnancy

Information & Discussion

Dr. Mark Thompson (CDC/NCIRD)

Fluzone Quadrivalent 0.5-mL dose for children aged 6 through 35 Months

Dr. Monica Mercer (Sanofi Pasteur)

#### **12:15 Rabies**

Workgroup update

Information

Dr. Sharon Frey (ACIP, WG Chair)

#### **12:20 Meningococcal**

Workgroup Update

Information

Dr. David Stephens (ACIP, WG Chair)

#### **12:25 Pertussis**

Introduction to Work Group

Dr. Henry Bernstein (ACIP, WG Chair)

Background to current ACIP recommendations (Td and Tdap) and policy considerations for Tdap revaccination

Information

Dr. Fiona Havers (CDC/NCIRD)

Adacel revaccination safety and immunogenicity

Dr. David Greenberg (Sanofi Pasteur)

Boostrix revaccination safety and immunogenicity

Dr. Leonard Silverstein (GSK)

#### **1:30 Public Comment**

#### **1:45 Adjourn**

#### **Acronyms**

9vHPV

9-Valent Human Papillomavirus Vaccine

CDC

Centers for Disease Control & Prevention

CMS

Centers for Medicare and Medicaid Services

DoD

Department of Defense

DVA

Department of Veterans Affairs

FDA

Food and Drug Administration

GRADE

Grading of Recommendations Assessment, Development and Evaluation

HRSA

Health Resources and Services Administration

IHS

Indian Health Service

IPD

Invasive pneumococcal disease

JE-VC

Vero cell culture-derived Japanese encephalitis vaccine

NCHHSTP

National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]

NCIRD

National Center for Immunization & Respiratory Diseases [of CDC/OID]

NCEZID

National Center for Emerging and Zoonotic Diseases [of CDC/OID]

NVPO

National Vaccine Program Office

PEP

Post-exposure prophylaxis

PCV13

13-valent pneumococcal conjugate vaccine

Td

Tetanus and diphtheria vaccine

Tdap

Tetanus, diphtheria, and pertussis vaccine

VFC

Vaccines for Children

WG

Work Group